EU Regulatory Correction in Medicine Authorization: What Pharmaceutical and Veterinary Companies Must Review in 2026

Key data

Pharmaceutical companies and veterinary laboratories operating under community authorization procedures have a new document review obligation following the publication, on 5 August 2026, of the error correction to Regulation (EU) 2019/5. The correction affects the text originally published in the Official Journal L 4 of 7 January 2019 and is available on EUR-Lex with the reference OJ:L_202690662.

Although the immediate practical impact is limited—the underlying procedures and authorization requirements are not altered—the correction has direct legal relevance: any discrepancy between a company's internal procedures and the corrected text can create legal uncertainty in files submitted to the European Medicines Agency (EMA).

What does this regulation establish?

Regulation (EU) 2019/5 was approved on 11 December 2018 with the aim of modernizing the European framework for medicine authorization. It modified three fundamental rules of European pharmaceutical law:

The correction published in August 2026 does not alter the regulatory substance of any of these three rules. Its scope is limited to technical or editorial adjustments identified in the text of Regulation (EU) 2019/5 since its original publication. The stated objective is to ensure legal certainty in marketing authorization procedures.

Economic and operational impact

The direct economic impact of this correction is low: it does not introduce new fees, does not modify authorization timelines, and does not alter the technical requirements of files. However, it has concrete operational implications for regulatory departments:

• Internal document review: Standard operating procedures (SOPs) that reference the text of Regulation (EU) 2019/5 must be updated to reflect the corrected version.
• Files submitted to the EMA: Any marketing authorization file in progress or future must be based on the corrected text to avoid formal objections.
• Legal certainty: Companies that maintain documentation based on the original text from January 2019 assume a minor but real legal risk in the event of inspection or regulatory litigation.
• Adaptation cost: The cost is primarily internal time for the regulatory team, with no significant economic investment.

Who does it affect?

• Pharmaceutical laboratories with medicines authorized or in the process of authorization through the centralized procedure with the EMA.
• Veterinary laboratories that market or request authorization for veterinary medicines in the EU.
• Regulatory Affairs Departments of pharmaceutical and veterinary companies with operations in the European Union.
• National regulatory authorities for medicines (in Spain, the Spanish Agency for Medicines and Health Products, AEMPS) that apply the community framework.
• Consultancies and law firms specialized in pharmaceutical and regulatory law that advise companies in the sector.
• Companies with pediatric medicines authorized under Regulation (EC) No 1901/2006, given that this was also modified by Regulation (EU) 2019/5 now corrected.

Practical example

A Spanish pharmaceutical laboratory with several medicines authorized through the centralized procedure with the EMA has in its quality system a standard operating procedure that expressly cites Regulation (EU) 2019/5 in its January 2019 version (OJ L 4 of 7.1.2019).

Following the publication of this correction on 5 August 2026, the Regulatory Affairs department must:

1. Download the corrected text from EUR-Lex (OJ:L_202690662).
2. Identify which articles or paragraphs have been subject to correction.
3. Update the internal SOPs that reference those articles.
4. Document the change in the quality management system with the date of the official correction.

The operational cost is low—a few hours of the regulatory team's time—but omitting this step can generate a non-conformity in an internal audit or a formal objection in a file submitted to the EMA.

What should companies do now?

1. Download the corrected text: Access EUR-Lex with the reference OJ:L_202690662 and obtain the official updated version of Regulation (EU) 2019/5.
2. Compare with the original text: Identify the articles or paragraphs affected by the correction to determine if they impact the company's internal procedures.
3. Review internal regulatory documentation: Update the SOPs, dossiers and files that cite Regulation (EU) 2019/5 to reflect the corrected text.
4. Inform the regulatory team: Communicate the change to those responsible for Regulatory Affairs, Quality and Legal so they can act in a coordinated manner.
5. Document the update: Record in the quality management system the date of the official correction (5 August 2026) and the actions taken, as evidence for potential audits.
6. Verify files in progress with the EMA: If there are active marketing authorization requests, confirm that the submitted documentation is consistent with the corrected text.

Official source

Consult complete regulation in official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202690662